Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Current Assets (2016 - 2025)

Historic Current Assets for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $161.3 million.

  • Angiodynamics' Current Assets fell 798.98% to $161.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $161.3 million, marking a year-over-year decrease of 798.98%. This contributed to the annual value of $168.3 million for FY2025, which is 1289.97% down from last year.
  • According to the latest figures from Q4 2025, Angiodynamics' Current Assets is $161.3 million, which was down 798.98% from $156.7 million recorded in Q3 2025.
  • Angiodynamics' 5-year Current Assets high stood at $196.9 million for Q1 2024, and its period low was $127.7 million during Q1 2022.
  • For the 5-year period, Angiodynamics' Current Assets averaged around $160.3 million, with its median value being $160.1 million (2022).
  • In the last 5 years, Angiodynamics' Current Assets surged by 2905.67% in 2024 and then plummeted by 1289.97% in 2025.
  • Over the past 5 years, Angiodynamics' Current Assets (Quarter) stood at $132.2 million in 2021, then grew by 20.16% to $158.8 million in 2022, then rose by 16.77% to $185.5 million in 2023, then dropped by 5.45% to $175.4 million in 2024, then fell by 7.99% to $161.3 million in 2025.
  • Its Current Assets stands at $161.3 million for Q4 2025, versus $156.7 million for Q3 2025 and $168.3 million for Q2 2025.